Novo Nordisk Launches Obesity Medicine Wegovy® (Semaglutide 2.4mg) (MAL24126014AZ) in Malaysia: A Key Advancement in the Fight Against Obesity and Cardiovascular Risks for People Living with Overweight

Recently, I attended the launch event where Novo Nordisk announced the availability of Wegovy® (semaglutide 2.4 mg) (MAL24126014AZ) in Malaysia. The treatment is introduced as an adjunct option for adults living with obesity and overweight who have at least one weight-related comorbidity. The launch comes at a critical time, as findings from the National Health and Morbidity Survey (NHMS) 2023 show that nearly 54.4% of Malaysian adults are classified as living with overweight or obesity.